NewAmsterdam Pharma Co NV
NAMS
Company Profile
Business description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Contact
Gooimeer 2-35
NaardenNH1411 DC
NLDT: +31 352062971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
77
Stocks News & Analysis
stocks
Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing
North America was a notable blemish, down 2% on an organic basis.
stocks
Our view on Santos after production is ramped up
Barossa at 75% capacity and Pikka undergoing commissioning.
stocks
GE Aerospace earnings: No good deed goes unpunished
We’ve raised our fair value estimate of GE Aerospace stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.20 | 14.10 | 0.15% |
| CAC 40 | 8,148.89 | 79.72 | 0.99% |
| DAX 40 | 24,856.47 | 295.49 | 1.20% |
| Dow JONES (US) | 49,384.01 | 306.78 | 0.63% |
| FTSE 100 | 10,150.05 | 11.96 | 0.12% |
| HKSE | 26,629.96 | 44.90 | 0.17% |
| NASDAQ | 23,436.02 | 211.20 | 0.91% |
| Nikkei 225 | 53,688.89 | 914.25 | 1.73% |
| NZX 50 Index | 13,507.71 | 49.16 | -0.36% |
| S&P 500 | 6,913.35 | 37.73 | 0.55% |
| S&P/ASX 200 | 8,845.10 | 9.20 | 0.10% |
| SSE Composite Index | 4,122.58 | 5.64 | 0.14% |